神州細胞(688520.SH):公司後續將有不同管線的產品陸續推進到臨牀,打造可持續發展能力
格隆匯8月1日丨有投資者向神州細胞(688520.SH)提問:公司後續產品管線佈局?
神州細胞回覆:公司後續產品佈局分為幾方面:一是疫苗產品,包括已上市的二價新冠疫苗和四價新冠疫苗,在臨牀的HPV疫苗,臨牀前的多價肺炎結合疫苗、帶皰疫苗等;二是生物藥方面,包括:(1)血友病用藥,包括已上市的重組八因子、臨牀前的雙抗;(2)自免系統用藥,包括已上市的阿達木單抗、在臨牀的IL17抗體等;(3)腫瘤類用藥,包括已上市的CD20抗體、已上市的貝伐珠單抗、在臨牀的PD-1抗體、EGFR抗體、臨牀前的一系列單抗、雙抗和多抗等。公司後續將有不同管線的產品陸續推進到臨牀,打造可持續發展能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.